ATLANTA, June 4, 2015 /PRNewswire/ -- EndoChoice today announced the pricing of its initial public offering of 6,350,000 shares of its common stock at a price to the public of $15.00 per share. The offering is scheduled to close on June 10, 2015, subject to customary closing conditions. The underwriters for the offering will also have a 30-day option to purchase up to an additional 952,500 shares of EndoChoice common stock at the price to the public, less the underwriting discounts and commissions.
EndoChoice common stock is expected to begin trading on the New York Stock Exchange on June 5, 2015 under the symbol "GI". J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. William Blair and Stifel are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 4, 2015. The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204); or BofA Merrill Lynch, Attention: Prospectus Dept., 222 Broadway, New York, NY 10038, or: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Based in the Atlanta, Georgia area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® System (Fuse®).
EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
For more information:
David Gill, Chief Financial Officer